433 related articles for article (PubMed ID: 21119365)
1. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.
Sallinen H; Heikura T; Laidinen S; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
Int J Gynecol Cancer; 2010 Dec; 20(9):1498-505. PubMed ID: 21119365
[TBL] [Abstract][Full Text] [Related]
2. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Sallinen H; Heikura T; Koponen J; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
BMC Cancer; 2014 Sep; 14():696. PubMed ID: 25245329
[TBL] [Abstract][Full Text] [Related]
3. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
Huo J; Hu J; Liu G; Cui Y; Ju Y
Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
[TBL] [Abstract][Full Text] [Related]
7. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
8. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Li P; He Q; Luo C; Qian L
Int J Clin Exp Pathol; 2015; 8(1):660-4. PubMed ID: 25755760
[TBL] [Abstract][Full Text] [Related]
12. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
13. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
14. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
[TBL] [Abstract][Full Text] [Related]
15. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
16. Angiopoietin-2 (Ang-2) is a useful serum tumor marker for liver cancer in the Chinese population.
Chen Y; Wu Y; Zhang X; Zeng H; Liu Y; Wu Q; Chen Y; Zhu G; Pan Q; Jin L; Guo L; Sun F
Clin Chim Acta; 2018 Mar; 478():18-27. PubMed ID: 29253494
[TBL] [Abstract][Full Text] [Related]
17. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
18. Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level.
Lyu N; Wang Y; Wang J; Zhang Z; Kong W
J Cancer Res Ther; 2018 Jun; 14(Supplement):S444-S449. PubMed ID: 29970704
[TBL] [Abstract][Full Text] [Related]
19. [Protein levels and its clinical significance of septin-9 and clusterin in peripheral blood of epithelial ovarian cancer patients].
Lyu N; Yao H; Xiao T; Gao Y; Wu L
Zhonghua Fu Chan Ke Za Zhi; 2015 Sep; 50(9):679-84. PubMed ID: 26675395
[TBL] [Abstract][Full Text] [Related]
20. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]